{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:12:56Z","timestamp":1778649176428,"version":"3.51.4"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cisplatin induced hearing loss (CIHL) affects 50-70% of all cisplatin-treated children. Cisplatin containing regimens often include various supportive care drugs and chemotherapeutic agents. No structured overview is available of the potential impact of concomitant medication, administered alongside cisplatin, on the increased risk of CIHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review, based on a PubMed (Medline), EMBASE, and Cochrane CENTRAL search, was conducted to summarize the effect of concomitant chemotherapeutic agents and supportive care drugs on developing hearing loss in cisplatin-treated pediatric cancer patients. The studies were categorized according to type of comedication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our review identified 27 relevant studies with a total of 7007 patients. There is heterogeneity among the included studies with respect to design and quality. Nevertheless, the results of the meta-analyses showed that vincristine (OR: 3.80, 95% CI: 2.86-5.04), furosemide (OR: 1.63, 95% CI: 1.14-2.33), aminoglycosides (OR: 1.72, 95% CI: 1.14-2.60) and vancomycin (OR: 1.63, 95% CI: 1.09-2.45) were recurrently found to be associated with an increased risk of CIHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review represents the first comprehensive overview of evidence on the contribution of comedication to the risk of CIHL. Vincristine, furosemide, ahminoglycosides, and vancomycin are associated with an increased risk of CIHL in pediatric cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1769234","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:47:16Z","timestamp":1778647636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Kim E.","family":"de Jager","sequence":"first","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology","place":["Utrecht, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nienke","family":"Streefkerk","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology","place":["Utrecht, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander E.","family":"Hoetink","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology","place":["Utrecht, Netherlands"]},{"name":"Department of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Utrecht, Utrecht University","place":["Utrecht, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm","family":"van Tinteren","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology","place":["Utrecht, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"van Grotel","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology","place":["Utrecht, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marry M.","family":"van den Heuvel-Eibrink","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology","place":["Utrecht, Netherlands"]},{"name":"Division of Child Health, Wilhelmina Children\u2019s Hospital","place":["Utrecht, Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.101662","article-title":"Childhood cancer: Estimating regional and global incidence","volume":"71","author":"Johnston","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.04.011","article-title":"Increasing incidence of cancer and stage migration towards advanced disease in children and young adolescents in the Netherlands, 1990\u20132017","volume":"134","author":"Reedijk","year":"2020","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.09.030","article-title":"Site of childhood cancer care in the Netherlands","volume":"87","author":"Reedijk","year":"2017","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29779","article-title":"Ototoxicity and cancer therapy","volume":"122","author":"Landier","year":"2016","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2006.09.015","article-title":"Mechanisms of cisplatin-induced ototoxicity and prevention","volume":"226","author":"Rybak","year":"2007","journal-title":"Hear Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.009","article-title":"Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose","volume":"40","author":"Li","year":"2004","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/mpo.2950190415","article-title":"Cisplatin ototoxicity in children: A practical grading system","volume":"19","author":"Brock","year":"1991","journal-title":"Med Pediatr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851015)56:8<1934::AID-CNCR2820560807>3.0.CO;2-F","article-title":"Ototoxicity of low- and moderate-dose cisplatin","volume":"56","author":"Schaefer","year":"1985","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2020.110401","article-title":"Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer","volume":"138","author":"Rajput","year":"2020","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801109","article-title":"Sodium thiosulfate for protection from cisplatin-induced hearing loss","volume":"378","author":"Brock","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s1470-2045(16)30625-8","article-title":"Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (Accl0431): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Freyer","year":"2017","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70046","article-title":"A retrospective evaluation of ototoxicity monitoring in a cohort of pediatric patients with solid tumors, treated in the Dutch National Cancer Center","volume":"7","author":"Diepstraten","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B13","article-title":"Cisplatin","volume-title":"Statpearls","author":"Gold","year":"2025"},{"key":"B14","article-title":"Protocol development","volume-title":"Tables of possible side effects for commonly-used oncology regimens","year":"2025"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.17430\/JHS.2020.10.2.1","article-title":"Ototoxicity as a side-effect of drugs: Literature review","volume":"10","author":"Skarzynska","year":"2020","journal-title":"J Hear Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MOO.0b013e3282ef772d","article-title":"Aminoglycoside ototoxicity","volume":"15","author":"Rizzi","year":"2007","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010181.pub2","article-title":"Platinum-induced hearing loss after treatment for childhood cancer","volume":"2016","author":"van As","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.joto.2016.10.001","article-title":"Ototoxic effects and mechanisms of loop diuretics","volume":"11","author":"Ding","year":"2016","journal-title":"J Otol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0030-6665(20)30770-2","article-title":"Ototoxicity of loop diuretics#","volume":"26","author":"Rybak","year":"1993","journal-title":"Otolaryngol Clinics North America"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199607000-00005","article-title":"A prospective cohort study of the effect of vincristine on audition","volume":"7","author":"Lugassy","year":"1996","journal-title":"Anti-Cancer Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2000.12.6.530","article-title":"Bilateral transient hearing loss associated with vincristine therapy: Case report","volume":"12","author":"Aydogdu","year":"2000","journal-title":"J Chemother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab184","article-title":"Aminoglycoside- and glycopeptide-induced ototoxicity in children: A systematic review","volume":"3","author":"Diepstraten","year":"2021","journal-title":"JAC-Antimicrob Resist"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210646","article-title":"A comparison of the Muenster, Siop Boston, Brock, Chang and Ctcaev4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy","volume":"14","author":"Clemens","year":"2019","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Internal Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604.ch10","article-title":"Analysing data and undertaking meta-analyses","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks","year":"2019"},{"key":"B27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2016.09.023","article-title":"Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A Dcog late-effects study","volume":"69","author":"Clemens","year":"2016","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/biomedicines11020261","article-title":"Early and long-term ototoxicity noted in children due to platinum compounds: Prevalence and risk factors","volume":"11","author":"Romano","year":"2023","journal-title":"Biomedicines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2021.5012","article-title":"Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin","volume":"64","author":"Sriyapai","year":"2022","journal-title":"Turk J Pediatr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000002158","article-title":"Evaluation of risk factors causing ototoxicity in childhood cancers located in the head and neck region treated with platinum-based chemotherapy","volume":"43","author":"Olgun","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2016.09.001","article-title":"Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients","volume":"90","author":"Olgun","year":"2016","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/fpc.0000000000000212","article-title":"Replication of a genetic variant in Acyp2 associated with cisplatin-induced hearing loss in patients with osteosarcoma","volume":"26","author":"Vos","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ng.478","article-title":"Genetic variants in Tpmt and Comt are associated with hearing loss in children receiving cisplatin chemotherapy","volume":"41","author":"Ross","year":"2009","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182707fc5","article-title":"Cisplatin-induced ototoxicity in pediatric solid tumors: The role of glutathione S-transferases and megalin genetic polymorphisms","volume":"35","author":"Choeyprasert","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.80","article-title":"Replication of Tpmt and Abcc3 genetic variants highly associated with cisplatin-induced hearing loss in children","volume":"94","author":"Pussegoda","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000001085","article-title":"Role of cisplatin dose intensity and Tpmt variation in the development of hearing loss in children","volume":"45","author":"Siemens","year":"2023","journal-title":"Ther Drug Monit"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000031627","article-title":"Platinum-induced ototoxicity in pediatric cancer survivors: Gstp1 C.313a>G variant association","volume":"101","author":"Sherief","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2014.06.007","article-title":"Hearing loss in Mexican children treated with cisplatin","volume":"78","author":"Castel\u00e1n-Mart\u00ednez","year":"2014","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-05098-7","article-title":"Impact of partial substitution of cisplatin with cyclophosphamide on acute toxicities in standard-risk medulloblastoma","volume":"174","author":"Metwally","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901015)66:8<1703::aid-cncr2820660809>3.0.co;2-v","article-title":"Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study Coss-86)","volume":"66","author":"Winkler","year":"1990","journal-title":"Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2023.100017","article-title":"Hearing loss after exposure to vincristine and platinum-based chemotherapy among childhood cancer survivors","volume":"1","author":"Strebel","year":"2023","journal-title":"EJC Paediatric Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33848","article-title":"The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments","volume":"128","author":"Meijer","year":"2022","journal-title":"Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-4642(21)00020-1","article-title":"Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: A multi-institutional North American cohort study","volume":"5","author":"Moke","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115869","article-title":"Influence of genetic variants in Tpmt and Comt associated with cisplatin induced hearing loss in patients with cancer: Two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts","volume":"9","author":"Hagleitner","year":"2015","journal-title":"PLoS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31189","article-title":"Long-term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (Ccss)","volume":"71","author":"Becktell","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4980","article-title":"Phase iii study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"24","author":"Packer","year":"2006","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1044\/2023_aja-22-00157","article-title":"Is methotrexate ototoxic? Investigating the ototoxic late effects of pediatric cancer treatment","volume":"32","author":"Moore","year":"2023","journal-title":"Am J Audiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03968-2","article-title":"Cisplatin ototoxicity in children: Risk factors and its relationship with polymorphisms of DNA repair genes Ercc1, Ercc2, and Xrcc1","volume":"84","author":"Turan","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.2038","article-title":"Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales\u2014a report from the Children's Oncology Group","volume":"32","author":"Landier","year":"2014","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21875","article-title":"Ototoxicity in children treated for osteosarcoma","volume":"52","author":"Lewis","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1990.8.7.1191","article-title":"Ototoxicity of preradiation cisplatin for children with central nervous system tumors","volume":"8","author":"Kretschmar","year":"1990","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/aud.0000000000001592","article-title":"Roadmap to a global template for implementation of ototoxicity management for cancer treatment","volume":"46","author":"Fernandez","year":"2025","journal-title":"Ear Hearing"},{"key":"B54","first-page":"2","article-title":"American Academy of Audiology position statement and clinical practice guidelines: Ototoxicity monitoring","author":"Durrant","year":"2009","journal-title":"Am Acad Audiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/bf01732887","article-title":"Sensorineural hearing loss associated with vincristine treatment","volume":"61","author":"Lugassy","year":"1990","journal-title":"Blut"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.66.778.688","article-title":"Partially reversible nerve deafness due to vincristine","volume":"66","author":"Yousif","year":"1990","journal-title":"Postgrad Med J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2005.10.011","article-title":"The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions","volume":"70","author":"Riga","year":"2006","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3329\/bjmed.v27i1.28068","article-title":"Does vincristine affect cochlear function in children with acute lymphoblastic leukaemia","volume":"27","author":"Rao","year":"2016","journal-title":"Bangladesh J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03884-5","article-title":"Aspects of vincristine-induced neuropathy in hematologic Malignancies: A systematic review","volume":"84","author":"Madsen","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B61","first-page":"2416","article-title":"Vincristine-induced peripheral neuropathy in pediatric cancer patients","volume":"6","author":"Mora","year":"2016","journal-title":"Am J Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2020.10.004","article-title":"Vincristine-induced peripheral neuropathy: A mini-review","volume":"81","author":"Li","year":"2020","journal-title":"Neurotoxicology"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.3928\/0191-3913-19790501-15","volume-title":"Unilateral optic neuropathy following vincristine chemotherapy","author":"Norton","year":"1979"},{"key":"B64","article-title":"Vincristine-induced blindness: A case report and review of literature","volume":"34","author":"Adhikari","year":"2014","journal-title":"Anticancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810515)47:10<2404::AID-CNCR2820471014>3.0.CO;2-2","article-title":"Acute acoustic nerve palsy associated with vincristine therapy","volume":"47","author":"Mahajan","year":"1981","journal-title":"Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.36.9744","article-title":"Carboplatin-associated ototoxicity in children with retinoblastoma","volume":"30","author":"Qaddoumi","year":"2012","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051266","article-title":"Assessment and management of platinum-related ototoxicity in children treated for cancer","volume":"12","author":"Romano","year":"2020","journal-title":"Cancers"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31815d1d83","article-title":"Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens","volume":"30","author":"Dean","year":"2008","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/937861","article-title":"Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection","volume":"2011","author":"Huth","year":"2011","journal-title":"Int J Otolaryngol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.3390\/ijms25084146","article-title":"Role of oxidative stress in sensorineural hearing loss","volume":"25","author":"Teraoka","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/ph16101353","article-title":"Aminoglycosides-related ototoxicity: Mechanisms, risk factors, and prevention in pediatric patients","volume":"16","author":"Rivetti","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1990.01870010065019","article-title":"Augmented gentamicin ototoxicity induced by vancomycin in Guinea pigs","volume":"116","author":"Brummett","year":"1990","journal-title":"Arch Otolaryngol\u2013Head Neck Surg"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/aac.9.6.956","article-title":"Ototoxicity of amikacin","volume":"9","author":"Black","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/0002-9343(86)90486-9","article-title":"Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin","volume":"80","author":"Lerner","year":"1986","journal-title":"Am J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2471\/blt.21.286823","article-title":"Prevention and management of hearing loss in patients receiving ototoxic medications","volume":"100","author":"Lindeborg","year":"2022","journal-title":"Bull World Health Organ"},{"key":"B76","volume-title":"Who consolidated guidelines on tuberculosis: Module 4: Treatment - drug-resistant tuberculosis treatment","year":"2020"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-199604000-00003","article-title":"Ototoxicity resulting from combined administration of cisplatin and gentamicin","volume":"106","author":"Riggs","year":"1996","journal-title":"Laryngoscope"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199107000-00004","article-title":"Toxic effects of cisplatin alone and in combination with gentamicin in stria vascularis of Guinea pigs","volume":"101","author":"Kohn","year":"1991","journal-title":"Laryngoscope"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02436-x","article-title":"Aminoglycoside-related nephrotoxicity and ototoxicity in clinical practice: A review of pathophysiological mechanism and treatment options","volume":"40","author":"Le","year":"2023","journal-title":"Adv Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/jcma.0000000000001023","article-title":"Otoprotection against aminoglycoside- and cisplatin-induced ototoxicity focusing on the upstream drug uptake pathway","volume":"87","author":"Hsieh","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piab111","article-title":"From \u201cmore is better\u201d to \u201cless is more\u201d: A commentary on antimicrobial use in pediatric oncology","volume":"11","author":"Wattier","year":"2022","journal-title":"J Pediatr Infect Dis Soc"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.316948","article-title":"Liposomal amphotericin B-induced reversible ototoxicity in a patient with disseminated histoplasmosis","volume":"53","author":"Ramu","year":"2021","journal-title":"Indian J Pharmacol"},{"key":"B83","article-title":"Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy","volume":"31","author":"Chen","year":"2008","journal-title":"Chang Gung Med J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2174\/092986711797535254","article-title":"Ototoxicity: Mechanisms of cochlear impairment and its prevention","volume":"18","author":"Tabuchi","year":"2011","journal-title":"Curr Med Chem"},{"key":"B85","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/cpt.603","article-title":"Drug-induced ototoxicity: Mechanisms, pharmacogenetics, and protective strategies","volume":"101","author":"Lanvers-Kaminsky","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23275","article-title":"Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach","volume":"58","author":"Orgel","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.6738","article-title":"Hearing loss in patients who received cranial radiation therapy for childhood cancer","volume":"34","author":"Bass","year":"2016","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.01.050","article-title":"Hearing loss after radiotherapy for pediatric brain tumors: Effect of cochlear dose","volume":"72","author":"Hua","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235749","article-title":"Patterns of hearing loss in irradiated survivors of head and neck rhabdomyosarcoma","volume":"14","author":"Diepstraten","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4274\/jbuch.galenos.2024.88310","article-title":"Evaluation of infectious complications and their causative agents in pediatric cancer patients: A prospective single-center cohort study","volume":"14","author":"Besin","year":"2024","journal-title":"J Beh\u00e7et Uz Children's Hosp (Online)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.077","article-title":"Relationship between cisplatin administration and the development of ototoxicity","volume":"24","author":"Rademaker-Lakhai","year":"2006","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.226","article-title":"Analysis of Risk Factors for Cisplatin-Induced Ototoxicity in Patients with Testicular Cancer","volume":"77","author":"Bokemeyer","year":"1998","journal-title":"British Journal of Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1769234\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:47:34Z","timestamp":1778647654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1769234\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":92,"alternative-id":["10.3389\/fonc.2026.1769234"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1769234","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1769234"}}